Absci Corp(ABSI) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.8 | Insider Own | 13.68% | Shs Outstand | 171.6M | Perf Week | 18.33% |
| Market Cap | 2.04B | Forward P/E | - | EPS next Y | 8.77% | Insider Trans | 0.21% | Shs Float | 148.1M | Perf Month | 17.16% |
| Enterprise Value | 1.84B | PEG | - | EPS next Q | -0.19 | Inst Own | 83.67% | Short Float | 24.99% | Perf Quarter | 55.5% |
| Income | -0.12B | P/S | 1306.91 | EPS this Y | 4.79% | Inst Trans | 19.49% | Short Ratio | 10.64 | Perf Half Y | 152.23% |
| Sales | 0.00B | P/B | 8.28 | EPS next 5Y | 10.61% | ROA | -50.57% | Short Interest | 37.02M | Perf YTD | 240.4% |
| Book/sh | 1.43 | P/C | 10.14 | EPS past 3/5Y | 9.99% -9.45% | ROE | -57.72% | 52W High | -1.45% ($12.06) | Perf Year | 170% |
| Cash/sh | 1.17 | P/FCF | - | Sales past 3/5Y | -21.31% -10.14% | ROIC | -48.87% | 52W Low | 430.36% ($2.24) | Perf 3Y | 873.77% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 15.36% | Gross Margin | -610.7% | Volatility(W/M) | 10.92% 9.65% | Perf 5Y | -16.92% |
| Dividend TTM | - | EV/Sales | 1180.43 | Sales Y/Y TTM | -62.28% | Oper. Margin | -8411.27% | ATR (14) | 0.91 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 10.63 | EPS Q/Q | 11.98% | Profit Margin | -7756.37% | RSI (14) | 64.28 | Recom | 1.18 |
| Dividend Gr. 3/5Y | - | Current Ratio | 10.63 | Sales Q/Q | -46.37% | SMA20 | 22.05% ($9.73) | Beta | 2.24 | Target Price | $14.9 |
| Payout | - | Debt/Eq | 0.02 | Earnings | 2026/11/12 | SMA50 | 26.01% ($9.43) | Rel Volume | 1.68 | Prev Close | $10.57 |
| Employees | 140 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | -9.95% -67.38% | SMA200 | 85.44% ($6.41) | Avg Volume(3M) | 3.48M | Price | $11.88 |
| IPO | 2021/7/22 | Option/Short | Yes/Yes | Trades | 25627 | Volume | 5,832,968 | Change | 12.39% |
🧬 AbSci (ABSI) is an AI-driven drug creation company that designs antibody therapeutics by combining generative artificial intelligence (AI) with its own wet-lab experiments. Through its integrated drug creation platform, the company rapidly connects the computational design stage to laboratory validation leads, while internally developing an early-stage pipeline in oncology and immune/inflammatory diseases and expanding its technology through partnerships with global pharmaceutical companies.
Over the past 1 year, on the higher side
1% below its 1-year high.
Traded more than usual. That is 168% of its average volume.
Next earnings report: November 12
14 days to go.
ABSI has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +4.8% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $130,691. Peers typically go for $1,237.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -16.9%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
25.0% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
It ranks #103 of 594 in the industry
Based on market cap of $2B.
FAQ
What kind of company is ABSI?
ABSI belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ABSI?
The market cap of ABSI is approximately $2.0B, ranking 2,049 within its sector.
What is the 52-week high and low for ABSI?
ABSI has recorded a 52-week high of $12.06 and a low of $2.24.
